Log in

NASDAQ:NRCIB - National Research Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume20,669 shs
Average Volume1,844 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
National Research Corporation provides analytics and insights that facilitate measurement and enhancement of the patient and employee experience in the United States and Canada. Its portfolio of subscription-based solutions provide actionable information and analysis to healthcare organizations and payers across a range of mission-critical, constituent-related elements, including patient experience, satisfaction, community population health risks, workforce engagement, community perceptions, and physician engagement. Read More…

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryHealth Care Services
SectorBusiness Services
Current SymbolNASDAQ:NRCIB
CUSIP63737230
Phone402-475-2525

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive NRCIB News and Ratings via Email

Sign-up to receive the latest news and ratings for NRCIB and its competitors with MarketBeat's FREE daily newsletter.


National Research (NASDAQ:NRCIB) Frequently Asked Questions

What is National Research's stock symbol?

National Research trades on the NASDAQ under the ticker symbol "NRCIB."

How were National Research's earnings last quarter?

National Research Co. (NASDAQ:NRCIB) posted its earnings results on Thursday, May, 4th. The business services provider reported $0.26 earnings per share for the quarter, missing analysts' consensus estimates of $0.81 by $0.55. The business services provider earned $30.28 million during the quarter. View National Research's Earnings History.

Has National Research been receiving favorable news coverage?

News coverage about NRCIB stock has trended extremely negative recently, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. National Research earned a daily sentiment score of -4.5 on InfoTrie's scale. They also gave news coverage about the business services provider a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the near term. View News Stories for National Research.

Who are some of National Research's key competitors?

What other stocks do shareholders of National Research own?

Who are National Research's key executives?

National Research's management team includes the folowing people:
  • Mr. Michael D. Hays, Founder, CEO & Director (Age 63)
  • Mr. Steven D. Jackson, Pres (Age 42)
  • Mr. Kevin R. Karas CPA, Principal Accounting Officer, Sr. VP of Fin., CFO, Treasurer & Sec. (Age 60)
  • Ms. Helen Hrdy, Sr. VP of Client Services

What is National Research's official website?

The official website for National Research is http://www.nrchealth.com/.

How can I contact National Research?

National Research's mailing address is 1245 Q STREET, LINCOLN NE, 68508. The business services provider can be reached via phone at 402-475-2525.


MarketBeat Community Rating for National Research (NASDAQ NRCIB)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  472 (Vote Outperform)
Underperform Votes:  454 (Vote Underperform)
Total Votes:  926
MarketBeat's community ratings are surveys of what our community members think about National Research and other stocks. Vote "Outperform" if you believe NRCIB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NRCIB will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel